Puma Biotech (PBYI) Tops Q1 EPS by 89c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Puma Biotechnology (PBYI) PT Lowered to $41 at Cowen
May 10, 2019 6:27 AM EDTCowen analyst Chris Shibutani lowered the price target on Puma Biotechnology (NASDAQ: PBYI) to $41.00 (from $56.00) while maintaining a Market Perform rating.
The analyst comments "1Q19 Nerlynx sales widely missed expectations owing to a mix of factors, some familiar (greater discontinuations), others more discomforting... More
